BioPharma Resources

Company · AZN

AstraZeneca

Includes drugs filed under related and acquired sponsor names. Trials are searched under: AstraZeneca; MedImmune LLC; Alexion Pharmaceuticals, Inc.; Acerta Pharma BV.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

84

47 still marketed

Novel approvals

39

Approvals since 2021

82

Originals and new uses

Phase 3 trials

894

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

Drugs in development (82)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • VolrustomigMEDI5752Phase 313 trials

    AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer

  • Savolitinibhmpl-504, AZD6094Phase 311 trials

    AstraZeneca · Carcinoma, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer

  • DomvanalimabAB154, GS-0154Phase 310 trials

    Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer

  • SaruparibAZD5305Phase 310 trials

    AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer

  • ApatinibRIVO, RivoceranibPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma

  • AtirmociclibPF-07220060Phase 39 trials

    Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

  • AZD0120GC012FPhase 39 trials

    AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis

  • ElecoglipronPhase 39 trials

    AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight

  • LenbelintideAZD6234Phase 39 trials

    AstraZeneca · Obesity or Overweight, Obesity, Overweight

  • SurovatamigAZD0486, TNB-486Phase 39 trials

    AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma

  • BCGPhase 38 trials

    ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis

  • OleclumabMEDI9447Phase 37 trials

    AstraZeneca · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Metastatic Microsatellite-stable Colorectal Cancer

  • AZD0780Phase 36 trials

    AstraZeneca · Cardiovascular Disease, Dyslipidaemia, Heterozygous Familial Hypercholesterolaemia

  • AZD0901Sonesitatug vedotin, CMG901Phase 36 trials

    AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma

  • TozorakimabMEDI3506Phase 36 trials

    AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure

  • CeralasertibAZD6738Phase 35 trials

    AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer

  • ALXN2220Phase 34 trials

    AstraZeneca · Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Transthyretin Amyloid Cardiomyopathy, Amyloid Transthyretin Cardiomyopathy

  • AZD5335Torvutatug samrotecan, Torvu-samPhase 34 trials

    AstraZeneca · Epithelial Ovarian Cancer, Ovarian Cancer, Lung Adenocarcinoma

  • BFFBFF MDI 320, BFF MDI 160Phase 34 trials

    AstraZeneca · Asthma

  • MonalizumabIPH2201Phase 34 trials

    AstraZeneca · Non-small Cell Lung Cancer, Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck

  • ALXN1850Phase 33 trials

    AstraZeneca · Hypophosphatasia

  • BGF MDI 320BGFPhase 33 trials

    AstraZeneca · Asthma, COPD (Chronic Obstructive Pulmonary Disease)

  • LHRHLuteinizing hormone-releasing hormone agonist, Luteinizing Hormone-Releasing Hormone AgonistsPhase 33 trials

    AstraZeneca · ER-Positive HER2-Negative Breast Cancer, Ovarian Cancer

  • Oteracil Potassiumgimeracil], S-1 [TegafurPhase 33 trials

    AstraZeneca · Biliary Tract Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma, Malignant Neoplasms of Digestive Organs

Recruiting Phase 3 trials

Largest first.

Marketed drugs (47)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.